TruSight Tumor 15 MiniSeq Kit
Focused sequencing panel to assess 15 genes that are commonly mutated in solid tumors in a single assay, with a simple, rapid workflow.
TruSight Tumor 15 uses next-generation sequencing (NGS) technology to provide a comprehensive assessment of 15 genes that are commonly mutated in solid tumors. It accurately detects low-frequency variants from 20 ng of starting DNA and is optimized for formalin-fixed, paraffin-embedded (FFPE) tumor tissue.
Specifications
| Assay Time | 7 hours |
|---|---|
| Hands-On Time | 3.5 hours |
| Input Quantity | 20 ng |
| Description | Focused panel to study relevant solid tumor somatic variants in 15 genes using a simple workflow. |
| Content Specifications | Amplifies 250 amplicons from 15 genes associated with solid tumors |
| Multiplexing | 1-24-plex |
| Cancer Type | Solid Tumor |
| Variant Class | Insertions-Deletions (indels), Somatic Variants |
| Specialized Sample Types | FFPE Tissue |
| Method | Amplicon Sequencing, Targeted DNA Sequencing |
| System Compatibility | MiniSeq, MiSeq, MiSeqDx in Research Mode |
| Nucleic Acid Type | DNA |
| Species Category | Human |
| Technology | Sequencing |
Project Recommendations
| Instrument | Recommended Number of Samples | Read Length |
|---|---|---|
| MiniSeq System | Samples per run: mid output: 2-3, high output: 8 (based on 93.5% of the bases covered at 500x minimum) | 2 × 150 bp (max recommended) |
| MiSeq System | 8 samples per run with v3 reagents (based on 93.5% of the bases covered at 500x minimum) | 2 × 151 bp (max recommended) |
20005610
Reviews
No customer reviews for the moment.
Focused sequencing panel to assess 15 genes that are commonly mutated in solid tumors in a single assay, with a simple, rapid workflow.